« Zurück
Startseite /
Ralimetinib dimesylate

Ralimetinib dimesylate

ArtNr	HY-13241-10mg
Hersteller	MedChem Express
CAS-Nr.	862507-23-1
Menge	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Glucose Homeostasis Molecular Targets for Neuroscience Targets for Rodent Neurosciences Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer Oligodendrocyte Markers
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.91
Formula	C26H37FN6O6S2
Citations	bioRxiv. 2023 Feb 8. Cell Death Dis. 2021 Oct 23;12(11):994. Cell Rep. 2023 Mar 20;42(3):112275. EBioMedicine. 2015 Nov 19;2(12):1944-56. Harvard Medical School LINCS LIBRARY Mol Cell Biol. 2025 Feb 2:1-17. Mol Med Rep 2019 Jul;20(1):735-744. Nat Commun. 2021 Dec 3;12(1):6941. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Cell Biol Int. 2019 Jul 19. Commun Biol. 2022 Dec 20;5(1):1391. Eur J Immunol. 2020 Sep;50(9):1350-1361. Glia. 2020 Jan;68(1):27-43. [1]Mader M, et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett, 2008, 18(1), 179-183. [2]Ishitsuka K, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol, 2008, 141(5), 598-606. [3]Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.
Smiles	FC1=CC=C(C=C1)C2=C(NC(C(C)(C)C)=N2)C3=NC4=C(C=C3)N=C(N)N4CC(C)(C)C.OS(C)(=O)=O.OS(C)(=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2228820 dimesylate
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	612.74
Product Description	Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 61 mg/mL (ultrasonic; warming)\|H2O : ≥ 33.33 mg/mL
Manufacturer - Pathway	Apoptosis; Autophagy; MAPK/ERK Pathway
Isoform	p38α; p38β
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-13241-10mg-safety-datasheet.pdf